Significance of HLA Antibody Detected by PRA-Bead Method in Kidney Transplant Outcomes

Transplantation Proceedings
P WiwattanathumV Sumethkul


The impact of specific HLA antibodies on the allograft function in the Luminex era is not clearly known. This study aimed to investigate kidney transplantation outcomes in patients with different anti-HLA antibody status as detected by Luminex PRA. This retrospective study included 106 deceased-donor kidney transplantation (DDKT) patients divided into 3 groups by PRA status as detected by PRA-bead: (1) PRA = 0; (2) positive PRA but with negative antibody against donor's HLA antigens; and (3) positive PRA with positive anti-HLA antibody specificity against donor's HLA antigens. There were 65, 23, and 18 patients in groups 1, 2, and 3, respectively. Early allograft rejections were highest in group 3 (22.2%) (P = .02). In multivariate analysis, delayed graft function was the only factor that was associated with allograft rejection (hazard ratio, 8.9; 95% confidence interval, 1.9-39.8; P = .004). Estimated glomerular filtration rates at 1 year of the 3 groups were 54.6, 55.8, and 60.0 mL/min (P = .71). One-year allograft failure and death were not different among the 3 groups. Expanded-criteria deceased donors were associated with both allograft failure (P = .003) and patient death (P = .02). Anti-HLA antibody as detected by Lumine...Continue Reading


Aug 1, 2000·Kidney International·H BoomL C Paul
Sep 21, 2011·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A SiedleckiD C Brennan
Feb 18, 2015·Transplant International : Official Journal of the European Society for Organ Transplantation·Isabel FonsecaDenisa Mendonça

Related Concepts

Transplanted Kidney
Stickler Syndrome, Type II (Disorder)
Allograft Rejection Pathway
Epidermal Growth Factor Receptor Activity
Cessation of Life
HLA Antigens
Delayed Graft Function

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.